{"title":"Effect of Disease-Modifying Treatments in Japanese Patients With Multiple Sclerosis During the Coronavirus Disease 2019 Pandemic","authors":"Taisuke Ogawa, Juichi Fujimori, Daisuke Kikuchi, Ichiro Nakashima","doi":"10.1111/cen3.70008","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Most disease-modifying treatments (DMTs) for patients with multiple sclerosis (PwMS) do not influence the risk and outcome of coronavirus disease (COVID-19), except for anti-CD20 monoclonal antibodies (ocrelizumab and rituximab). However, data on Japanese PwMS are lacking. Thus, we evaluated the risk of COVID-19 in Japanese PwMS undergoing DMTs.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this retrospective cross-sectional study, we used the Japanese administrative database. The incidence of COVID-19 between January 1, 2022, and December 31, 2024 was compared between PwMS who were administered different DMTs.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In total, 61 of 1044 (5.8%) PwMS who were administered baseline treatments and 102 of 1253 (8.1%) PwMS who were administered high-efficacy treatments had COVID-19. The prevalence of COVID-19 was significantly higher in PwMS receiving high-efficacy treatments than in those receiving baseline treatments. However, this prevalence did not differ significantly among PwMS on different individual DMTs.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Although high-efficacy therapy may increase the overall prevalence of COVID-19, no specific DMT approved in Japan was associated with an increased prevalence of COVID-19 among Japanese PwMS.</p>\n </section>\n </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Neuroimmunology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen3.70008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives
Most disease-modifying treatments (DMTs) for patients with multiple sclerosis (PwMS) do not influence the risk and outcome of coronavirus disease (COVID-19), except for anti-CD20 monoclonal antibodies (ocrelizumab and rituximab). However, data on Japanese PwMS are lacking. Thus, we evaluated the risk of COVID-19 in Japanese PwMS undergoing DMTs.
Methods
In this retrospective cross-sectional study, we used the Japanese administrative database. The incidence of COVID-19 between January 1, 2022, and December 31, 2024 was compared between PwMS who were administered different DMTs.
Results
In total, 61 of 1044 (5.8%) PwMS who were administered baseline treatments and 102 of 1253 (8.1%) PwMS who were administered high-efficacy treatments had COVID-19. The prevalence of COVID-19 was significantly higher in PwMS receiving high-efficacy treatments than in those receiving baseline treatments. However, this prevalence did not differ significantly among PwMS on different individual DMTs.
Conclusion
Although high-efficacy therapy may increase the overall prevalence of COVID-19, no specific DMT approved in Japan was associated with an increased prevalence of COVID-19 among Japanese PwMS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
